The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Weight Loss and Weight Regain in Usual Clinical Practice: Results From the TARGET-NASH Observational Cohort
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2393-2395.e4.doi: 10.1016/j.cgh.2021.01.023. Epub 2021 Jan 21.
2Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
3TARGET RWE, Durham, North Carolina.
4Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
5AdventHealth Translational Research Institute, Orlando, Florida.
6San Jose Gastroenterology, San Jose, California.
7Gastro Florida, Clearwater, Florida.
8Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
9NAFLD Research Center, Division of Gastroenterology, Department of Medicine, University of California at San Diego, San Diego, California.
10Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. Electronic address: aslok@med.umich.edu.
Abstract
First-line treatment for nonalcoholic fatty liver disease (NAFLD) focuses on weight loss through lifestyle modifications.<sup>1,2</sup> Weight loss ≥5% results in reduction of steatosis and weight loss ≥10% has been associated with improvement in hepatic inflammation and fibrosis.<sup>3</sup> The incidence and sustainability of weight loss among patients with NAFLD were estimated and associating factors identified.